Pure Global
NCT05408520

Targeted Muscle Reinnervation Study (TMR)

A Randomized Controlled Trial of Targeted Muscle Reinnervation in Patients Requiring Lower Extremity Amputation.
Joshua Hustedt·ClinicalTrials.gov·procedureRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Amputation
Drug/Device/Intervention
Targeted Muscle Reinnervation
Study type
Interventional
Intervention type
procedure
Sponsor & location
Primary sponsor
Joshua Hustedt
Funder
University of Arizona
Location
Phoenix, United States of America
Timeline & enrollment
Phase
N/A
Start date
Dec 01, 2022
End date
May 01, 2025
Enrollment
50 participants
Primary outcome

Effect of TMR on neuroma,Effect of TMR on phantom limb pain

Summary

The purpose of this study is to examine the effect of targeted muscle reinnervation on the
 outcomes of amputees at a level 1 trauma center. The investigators propose to randomize all
 patients requiring amputation with and without targeted muscle reinnervation. This study will
 help delineate the efficacy of targeted muscle reinnervation in the general population.

ICD-10 classifications
Amputation of limb(s)Traumatic amputation of both feetTraumatic amputation of upper and lower limbs, any combination [any level]Traumatic amputations involving other combinations of body regionsTraumatic amputation of lower leg
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT05408520
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT05408520 through Pure Global AI's free database. This phase not specified trial is sponsored by Joshua Hustedt and is currently Recruiting. The study focuses on Amputation. Target enrollment is 50 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.